Kozo Kataoka, Takeshi Yamada, Manabu Shiozawa, Naoto Takase, Kazuma Ito, Kentaro Yamazaki, Jun Watanabe, Toshihiro Kudo, Takeshi Suto, Toshihiko Matsumoto, Kohei Murata, Yusuke Suwa, Shogen Boku, Hisateru Yasui, Nobuhisa Matsuhashi, Atsuyuki Maeda, Kiichi Sugimoto, Yusuke Matsumoto, Mitsuru Yokota, Johannes Fredebohm, Keita Mori, Masataka Ikeda
BACKGROUND: Spatial and temporal heterogeneities of RAS and other molecular genes should be considered in the treatment of metastatic colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs); acquired RAS mutation is sometimes observed at disease progression of treatment with the anti-EGFR mAb. At the same time, discrepancy of RAS status from tissues and circulating tumor DNA (ctDNA) in the same patient is sometimes observed. Based on this, we commenced two observational studies to clarify these heterogeneities of RAS and BRAF in mCRC, using next generation sequencing from liquid biopsy...
2024: Journal of the Anus, Rectum and Colon